Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep-Dec;22(3):353-359.
doi: 10.4103/jomfp.JOMFP_174_17.

Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study

Pankaj M Shirsat  1 , Shivani Bansal  1 , Pooja Prasad  1 , Rajiv S Desai  1
Affiliations

Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study

Pankaj M Shirsat et al. J Oral Maxillofac Pathol. 2018 Sep-Dec.

Abstract

Background: Ameloblastoma is an uncommon, benign neoplasm of odontogenic epithelium commonly affecting the posterior mandible (almost 80%) particularly in the molar/ramus region, with occasional tumors involving the maxilla. Recently, there has been much interest generated after the reports of BRAF V600E mutations in ameloblastomas with a frequency of 46%-80% using both molecular as well as immunohistochemical (IHC) techniques. We sought to assess the presence of BRAF V600E expression in ameloblastomas in Indian patients and correlate the same with clinical behavior and histological variants by performing IHC analysis with anti-BRAF V600E antibody.

Materials and methods: Thirty formalin-fixed paraffin-embedded tissues of mandibular ameloblastomas were examined by anti-BRAF V600E antibody and correlated with clinicopathologic and histological parameters. Cytoplasmic staining of neoplastic epithelium was considered positive for BRAF V600E expression.

Statistical analysis: Data analysis was performed using Chi-square test and Student's t-test with statistical software IBM SPSS statistics 20.0.

Results: BRAF V600E antibody showed positive expression only in 33.3% (10/30) cases. About 66.7% (4/6) recurrent cases and 63.6% (7/11) plexiform cases showed statistically significant association of P = 0.05 and P = 0.021, respectively, among cases with positive BRAF V600E immunoexpression.

Conclusion: We report the lowest frequency (33.3%) of BRAF V600E immunoexpression in mandibular ameloblastomas in Indian population. However, a significant association of BRAF V600E-positive immunoexpression with recurrence and plexiform pattern could underline its role as a therapeutic marker for ameloblastoma.

Keywords: BRAF V600E; immunohistochemistry; mandibular ameloblastomas.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Immunohistochemical expression of BRAF V600E, ×40. (a) Positive control-papillary thyroid carcinoma, (b) plexiform variant, (c) desmoplastic variant and (d) granular cell variant of mandibular ameloblastomas
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McClary AC, West RB, McClary AC, Pollack JR, Fischbein NJ, Holsinger CF, et al. Ameloblastoma: A clinical review and trends in management. Eur Arch Otorhinolaryngol. 2016;273:1649–61. - PubMed
    1. Brown NA, Betz BL. Ameloblastoma: A Review of recent molecular pathogenetic discoveries. Biomark Cancer. 2015;7:19–24. - PMC - PubMed
    1. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. Am J Clin Oncol. 2007;30:645–8. - PubMed
    1. Kurppa KJ, Catón J, Morgan PR, Ristimäki A, Ruhin B, Kellokoski J, et al. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol. 2014;232:492–8. - PMC - PubMed
    1. Wright JM, Vered M. Update from the 4th edition of the world health organization classification of head and neck tumours: Odontogenic and maxillofacial bone tumors. Head Neck Pathol. 2017;11:68–77. - PMC - PubMed